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Background: In 2015, Bristol (South West England) experienced a large increase in cases of 
meticillin-resistant Staphylococcus aureus (MRSA) infection in people who inject drugs 
(PWID). 
Aim: We aimed to characterise and estimate the prevalence of MRSA colonisation among 
PWID in Bristol and test evidence of a clonal outbreak. 
Methods: PWID recruited through an unlinked-anonymous community survey during 2016 
completed behavioural questionnaires and were screened for MRSA. Univariable logistic 
regression examined associations with MRSA colonisation. Whole-genome sequencing used 
lineage-matched MRSA isolates, comparing PWID (screening and retrospective bacteraemia 
samples from 2012-2017) with non-PWID (Bristol screening) in Bristol and national 
reference laboratory database samples. 
Results: The MRSA colonisation prevalence was 8.7% (13/149) and was associated with 
frequently injecting in public places (odds ratio (OR): 5.5; 95% confidence interval (CI):1.34–
22.70), recent healthcare contact (OR: 4.3; 95% CI: 1.34–13.80) and injecting in groups of 
three or more (OR: 15.8; 95% CI: 2.51–99.28). People reporting any one of: injecting in 
public places, injection site skin and soft tissue infection or hospital contact accounted for 
12/13 MRSA positive cases (sensitivity 92.3%; specificity 51.5%). Phylogenetic analysis 
identified a dominant clade associated with infection and colonisation among PWID in 
Bristol belonging to ST5-SCCmecIVg. 
Conclusions: MRSA colonisation in Bristol PWID is substantially elevated compared with 
general population estimates and there is evidence of clonal expansion, community-based 
transmission and increased infection risk related to the colonising strain. Targeted 
interventions, including community screening and suppression therapy, education and basic 
infection control are needed to reduce MRSA infections in PWID. 
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Introduction 
Meticillin-resistant Staphylococcus aureus (MRSA) can exist as a harmless commensal or a 
potentially life-threatening pathogen [1,2]. Clinical presentations range from localised skin 
and soft tissue infections (SSTIs) to disseminated blood stream infections. These infections 
are responsible for substantial healthcare costs, morbidity and mortality [2-4]. The United 
Kingdom (UK) government have adopted a zero tolerance approach to avoidable healthcare 
associated infections with a focus on MRSA bacteraemia [5,6]. However, this approach is 
controversial as organisms can be introduced through multiple independent sources [5]. 
MRSA can survive in a range of ecological settings, interact with and colonise the human host 
and develop antimicrobial resistance via a range of mechanisms [4]. These traits allow MRSA 
to spread between populations and species exploiting niches and opening up footholds to 
establish reservoirs within different settings [4]. MRSA was initially thought to be confined to 
healthcare settings (HA-MRSA) but during the 1980s infections were noticed in the 
community (CA-MRSA) and in the early 2000s infections were also identified in humans 
associated with exposure to livestock (LA-MRSA) [1,7]. Colonising MRSA can be transmitted 
from person-to-person and introduced into the body when host defences are breached 
[1,8,9]. This is apparent in communities of people who inject drugs (PWID), with outbreaks 
previously reported in England and the United States (US) resulting in substantial morbidity 
and mortality [10-12]. Studies in Switzerland (2001), Canada (2006) and the US (2012) have 
found a high MRSA colonisation prevalence in PWID ranging from 5.7 to 18.6% [10,11,13]. 
These high prevalence estimates contrast sharply with general population estimates of < 0.1–
1.5% and appear to be driven in part by frequent healthcare contact [10,13-18]. 
In the UK and Europe there is limited information on the incidence of infection and prevalence 
of colonisation associated with MRSA in PWID. It has been shown that symptoms of probable 
SSTI at injection sites are common, with 36% of PWID reporting these in a national survey in 
2016 [19,20]. These reports, however, are not laboratory confirmed and do not provide 
information on the aetiological agent. Infections in PWID are often exacerbated through poor 
and/or delayed health-seeking behaviours, resulting in more serious and difficult to treat 
infections and substantial costs [21]. 
Bristol is a city in the South West of England with a population of 459,000; it is estimated that 
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there are between 2,025–2,564 persons injecting drugs [22]. Bristol has the highest 
prevalence of crack use and sixth highest opiate use in England [23]. 
In the second half of 2014 the health community in Bristol identified an increase in the 
number MRSA bacteremias occurring in PWID. The increase was initially reported by general 
practitioners but also detected through the hospital post infection review process. Following 
further investigation by the Field Epidemiology Service in Public Health England it was found 
that infections in PWID were a growing proportion of all MRSA cases reported in Bristol with 
the number more than doubling from 19 in 2013 to 45 in 2014, this increase was sustained in 
2015 (46 infections) and up to August 2016 (37 infections). Infections in PWID were often 
serious with a considerable number resulting in protracted hospital admissions, amputations 
and/or death. Between January 2014 and August 2016, 18% of all reported infections in PWID 
were bloodstream infections (data not shown). This increase in MRSA among PWID in Bristol 
was in contrast to the national decline in MRSA bacteraemia rates from 2007 to 2017 [24]. 
Only MRSA bacteraemia samples were routinely sent for typing and there was no information 
on colonisation within the community. We therefore aimed to estimate the prevalence of 
MRSA among PWID in Bristol, explore the genetic relatedness of these samples compared 
with other PWID MRSA bacteraemia isolates and non-PWID isolates, identify injecting and 
non-injecting risk factors associated with infection and provide evidence to inform 
development and/or implementation of population specific control interventions. The 
prospective study was initiated from January 2016, with data collection occurring for 6 weeks 
from October 2016. Retrospective bacteraemia isolates in PWID occurring between 2012 to 
2017 were examined. 
Methods 
Study population and setting 
In 2016, a cross-sectional survey of PWID living in the City of Bristol was undertaken in 
partnership with the national Unlinked Anonymous Monitoring (UAM) survey of PWID [25]. 
The UAM has been running since 1990 and is an annual cross-sectional survey that recruits 
PWID from across England, Wales and Northern Ireland. The methodological details have 
been reported previously [26,27]. 
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PWID in the City of Bristol were recruited through fixed site and mobile needle and syringe 
programme (NSP) using non-probability quota sampling [28]. The sample was purposely 
recruited to reflect age and sex data held by Bristol Drugs Project (BDP). BDP are a charity 
that provide drug and alcohol services within the City of Bristol. 
Data collection 
Recruited participants completed an expanded version of the UAM questionnaire, which had 
been piloted on a group of BDP service users. Information on age and sex, homelessness, prior 
imprisonment, psychoactive drug use, uptake of health services and sexual behaviours was 
collected and published in 2017 [29]. Questions were added according to a priori hypotheses 
relating to MRSA colonisation: living conditions (accommodation type, access to running 
water and living arrangements), injecting practice, such as injection site (arm, leg, groin, etc.) 
and the physical location (home, outside, squat, etc.) and person-to-person contact (numbers 
of injecting companions) and previous infections (SSTI and MRSA). Data were double entered 
from paper questionnaires into a validated Epidata v3.1 data collection form [30]. Data 
inconsistencies were checked against original paper forms by the data entry team. Data were 
cleaned and recoded using R v3.2.0 [31]. 
Data analysis 
People were excluded from the analysis if they did not report injecting in the past year or if 
they had already completed the UAM survey that year. We identified factors associated with 
MRSA colonisation using univariable logistic regression and calculated odds ratios (OR) and 
corresponding 95% confidence intervals (CI). 
We defined groups of people at greater risk of colonisation by examining combinations of risk 
factors chosen based upon the univariable analysis (OR > 2.5) and potential for targeting 
interventions. Factors representing recent MRSA colonisation were excluded. Risk factor 
combinations were assessed in terms of sensitivity, specificity, receiver operator curve (ROC) 
and positive predictive value (PPV). A ROC value of 0.70 or above was used as a threshold for 
inclusion [32]. 
Microbiological testing 
Trained BDP staff members collected groin and nasal swabs from participants. Swabs were 
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cultured onto Brilliance Staph 24 agar (Oxoid). Presumptive S.aureus were initially identified 
using matrix-assisted laser desorption ionization-time of flight mass spectrometry MALDI-TOF 
(Bruker Daltonik GmbH, Germany) and MRSA were identified by antibiotic susceptibility 
testing using VITEK 2 (software v07.01 and card name AST-P635, bioMérieux). Colonised 
participants were defined as people living in the City of Bristol who reported injecting within 
the last past year and found to be positive for MRSA colonisation in nasal and/or groin sites. 
Whole-genome sequence analysis Phylogenetic analysis 
All MRSA were subjected to WGS, bioinformatic and phylogenetic analysis as described 
previously, with N315 (NC002745) being used as reference [33]. Briefly, genomic DNA was 
extracted using the QIAsymphony platform (Qiagen, Hilden, Germany), fragmented and 
tagged for multiplexing with Nextera XT DNA Sample Preparation Kits, followed by paired-end 
sequencing on an Illumina HiSeq 2500 platform to produce 100 bp paired-end reads (Illumina, 
Cambridge, UK) and a coverage above 30x [33]. For phylogenetic analysis, sequence reads 
were mapped to the N315 reference strain (NC002745) using BWA(0.7.5). Single Nt 
Polymorphisms (SNPs) were called using GATK2.6.5. Genetic relatedness was determined 
using only high quality SNPs (AD genotype = 0.9). Coverage was above 95% of the reference 
genome. SNPs were concatenated and aligned allowing 20% of Ns and gaps. Clusters were 
defined by hierarchical clustering using single linkage and SNP threshold of 150 using 
fastcluster in R (Supplementary Table S1) [34]. Phylogeny was inferred from concatenated 
SNP alignment by using RaxML (Maximum Likelihood using GTR substitution model and 100 
bootstrap) [35]. The tree was visualised using interactive Tree Of Life (iTOL), pairwise SNP 
distance matrix was calculated excluding Ns and gaps (Supplementary Table S2). 
Bristol PWID colonisation isolates identified as belonging to a dominant MRSA clone were 
compared with lineage-matched isolates that had been subjected to WGS in the Antimicrobial 
Resistance and Healthcare Associated Infections Reference Unit in Public Health England 
(PHE), specifically: (i) retrospective Bristol PWID MRSA bacteraemia isolates, (ii) non-PWID 
MRSA carriage isolates from pre-admission screening swabs from the University Hospital 
Bristol (UHB) and (iii) contemporaneous representative MRSA from the PHE national 
reference laboratory archive. Susceptibility data were not available for these comparator 
isolates. The retrospective Bristol PWID bacteraemia isolates were identified through record 
linkage between drug services data and laboratory reports of all samples processed at UHB 
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laboratory from 2012 to 2016. Repeat, non-duplicate, infections were included and defined 
as any MRSA with a sample date greater than 14 days apart. Non-PWID UHB admission 
screening samples were selected from a convenience sample of MRSA positive UHB admission 
screening samples collected during October 2016. This time period was contemporaneous 
with the PWID swabbing element of the study. Details of the UHB screening criteria have been 
described previously [36]. These were checked against hospital records to ensure they were 
from people not reporting injecting drug use. PHE national reference laboratory archive 
isolates had information on the geographical location and presence of injecting risk factors 
collated. 
Descriptive statistics (mean, median, minimum, maximum and interquartile range), 
frequencies and percentages were used to compare epidemiological characteristics of people 
within and between clusters. 
Ethical statement 
Participants provided verbal consent when enrolled into the study. 
The study received ethical approval from the London research ethics committee (REC 
reference: 98/2/051). 
Results 
Study population 
There were 153 survey participants of which, 149 reported injecting in the past year (2015 to 
2016) and were included in the analysis. The majority of participants were male (84%; 
128/153) and were aged 35–44 years (46%; 71/153). The median age was similar for men (39, 
Interquartile range (IQR): 34.5–46) and women (40; IQR: 31–45). The majority (95%; 142/149) 
reported injecting in the past month, commonly with opioids (35%; 50/142) or opioids and 
stimulant combinations (30%; 42/142). Participants typically reported injecting into their 
arms (56%; 79/142) and/or groin (52%; 74/142); 44% (65/149) reported homelessness within 
the past year. Over a third (37%; 47/142) of people self-reported symptoms of a previous SSTI 
at their injection site in the past year. 
Of the participating PWID, 13 were colonised with MRSA, giving a prevalence of 8.7%. Twenty 
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of the 149 PWID reported a previous SSTI; 13 (10%; 13/136) in non-colonised and six (46/13) 
in colonised PWID all six reported a previous SSTI due to MRSA. Four of these occurred in the 
past 3 months and all reported being prescribed decolonisation therapy (nasal cream and 
body wash) in the past month. 
Of the non-colonised 136 participating PWID, 17 (13%) reported a previous MRSA infection, 
five of them within the past 3 months. Eleven of the 17 people reporting a previous infection 
reported a SSTI and four reported previous decolonisation. 
Factors associated with MRSA colonisation 
We identified several factors strongly associated with MRSA colonisation among PWID in 
Bristol. Participants who reported most frequently injecting in public places (OR: 5.5; 95% CI: 
1.34–22.70), hospital contact in the past month (OR: 4.3; 95% CI: 1.34–13.80), most 
frequently injecting in a group of three or more (OR: 15.8; 95% CI: 2.51–99.28) and 
experiencing an MRSA infection in the past 3 months (OR: 13.6; 95% CI: 2.98–62.17) were 
associated with MRSA colonisation. Weaker associations were identified for SSTI at an 
injecting site in past year (OR: 2.8; 95% CI: 0.89–8.85), homelessness in the past year (OR: 3.2; 
95% CI: 0.94–10.96), groin injecting (OR: 3.8; 95% CI: 0.99–14.23) and previous deep vein 
thrombosis (DVT) comorbidity (OR: 2.6; 95% CI: 0.81–8.18) (Table 1). 
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TABLE 1. Univariable analysis of factors associated with methicillin-resistant Staphylococcus aureus in colonisation, Bristol, 2016 (n = 149) 
Variable Value Neg % Pos % Total OR 95% CI 
Skin and soft tissue infection in the past year 
No 96 94.1 6 5.9 102 Ref NA 
Yes 40 85.1 7 14.9 47 2.8 0.89–8.85 
Most frequently injecting location 
House own/friend 75 94.9 4 5.1 79 Ref NA 
Hostel, squat, other 44 91.7 4 8.3 48 1.7 0.41–7.16 
Public places 17 77.3 5 22.7 22 5.5 1.34–22.73 
Hospital contact past month 
No 107 94.7 6 5.3 113 Ref NA 
Yes 29 80.6 7 19.4 36 4.3 1.34–13.8 
Homeless past year 
No 80 95.2 4 4.8 84 Ref NA 
Yes 56 86.2 9 13.8 65 3.2 0.94–10.96 
Groin inject in the past month 
No 72 96.0 3 4.0 75 Ref NA 
Yes 64 86.5 10 13.5 74 3.8 0.99–14.23 
Ever experienced a DVT co-morbidity 
No 102 93.6 7 6.4 109 Ref NA 
Yes 34 85.0 6 15.0 40 2.6 0.81–8.18 
Frequently inject in groups 
Own 79 94.0 5 6.0 84 Ref NA 
Less than three people 54 91.5 5 8.5 59 1.5 0.4–5.3 
Three or more people 3 50.0 3 50.0 6 15.8 2.51–99.28 
Previous MRSA Infection 
No previous infection 119 94.4 7 5.6 126 Ref NA 
> 3 months ago 12 85.7 2 14.3 14 2.8 0.53–15.2 
< 3 months ago 5 55.6 4 44.4 9 13.6 2.98–62.17 
CI: confidence interval; DVT: deep vein thrombosis; MRSA: meticillin-resistant Staphylococcus aureus; NA: not applicable; Neg: negative for MRSA colonisation; OR: odds 
ratio; Pos: positive for MRSA colonisation; Ref: reference. 
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Six indicators met our criteria for grouping: injecting in public places, hospital contact, 
injecting in a group of three or more people, SSTI, homelessness in the past year and groin 
injecting. We identified four groups according to different permutations of 4 of 6 indicator 
variables, which defined Bristol PWID with greater odds of MRSA colonisation with adequate 
sensitivity and specificity (ROC 0.7). Group 1 defined people who reported frequently injecting 
in public places or SSTI in past year or healthcare contact in past month. Group 2 people 
included people reporting injected in a group of three or more or frequently inject in public 
places or SSTI in past year or healthcare contact in past month. Group 3 included people with 
a SSTI in past year or healthcare contact in past month. Group 4 included people reporting 
injecting in a group of three or more or SSTI in past year or healthcare contact in past month. 
Group 1 and 2 best explained MRSA colonisation accounting for 12 of 13 colonised 
participants with high sensitivity (> 92%) and moderate specificity (≥ 50%) (Table 2). 
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TABLE 2. Univariable analysis of the association between clinical assessment group 
classifications and MRSA colonisation, sensitivity, specificity and positive predictive value 
in sampled PWID, 2016 
Group Value Neg Pos OR 95% CI P value Sensitivity (%) Specificity (%) ROC PPV (%) 
Group 1 
No 70 1 Ref NA NA NA NA NA NA 
Yes 66 12 12.57 1.77–551.65 0.004 92.3 51.5 0.72 15.4 
Group 2 
No 68 1 Ref NA NA NA NA NA NA 
Yes 68 12 11.86 1.67–520.34 0.005 92.3 50.0 0.71 15.0 
Group 3 
No 78 2 Ref NA NA NA NA NA NA 
Yes 58 11 7.31 1.51–70.36 0.008 84.6 57.4 0.71 15.9 
Group 4 
No 75 2 Ref NA NA NA NA NA NA 
Yes 61 11 6.69 1.38–64.35 0.011 84.6 55.1 0.70 15.3 
Total 136 13 NA NA NA NA NA NA NA 
CI: confidence interval; MRSA: meticillin-resistant Staphylococcus aureus; NA: not applicable; Neg: negative; 
OR: odds ratio; Pos: positive; PPV: positive predictive value; PWID: people who inject drugs; ref: reference; 
ROC: receiver operator curve; Ref: reference.; SSTI: Skin and soft tissue infections. 
Group 1 defined people who reported frequently injecting in public places or SSTI in past year or healthcare 
contact in past month. Group 2 people included people reporting injected in a group of three or more or 
frequently inject in public places or SSTI in past year or healthcare contact in past month. Group 3 included 
people with a SSTI in past year or healthcare contact in past month. Group 4 included people reporting 
injecting in a group of three or more or SSTI in past year or healthcare contact in past month. 
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Microbiological analysis 
In total, there were 16 Bristol PWID colonisation samples from our survey, 39 retrospective 
Bristol PWID bacteraemia samples and 25 non-PWID UHB admission screening samples. The 
16 Bristol PWID colonisation isolates were recovered from 13 survey participants and 
included two phenotypically distinct isolates from one participant and two who were positive 
at both nose and groin sites. Genomic analysis showed the majority of the Bristol PWID 
colonisation MRSA (12/16) belonged to multilocus sequence type 5 (ST5), encoded 
staphylococcal cassette chromosome mec type IVg (SCCmecIVg) and were PVL-negative. The 
remainder belonged to ST1-IV (n = 3) or ST3919-IV (n = 1; a single locus variant of ST8). 
Greater heterogeneity was apparent among the non-PWID UHB admission screening samples 
with eight of 25 belonging to multilocus sequence type clonal complex 5 (CC5); the remainder 
comprised CC22 (n = 8), CC30 (n = 4), CC1 (n = 3), CC8 (n = 1) and CC59 (n = 1). 
A phylogenetic tree of 71 ST5 MRSA (24 bacteraemia and 12 carriage isolates from PWID in 
Bristol, eight pre-admission screening swabs from UHB patients in Bristol and 27 from PHE 
national reference laboratory archives) is shown in Figure. The majority (68%; 48/71) 
belonged to a single lineage (ST5-SCCmecIVg) herein dubbed the ‘Bristol clade’. The ST5-IVg 
lineage has been infrequently noted it in hospitalised patients. Furthermore, the majority of 
bacteraemia cases observed in PWID are community onset (occurring < 48h following 
admission to hospital). 
FIGURE. Maximum-likelihood phylogenetic tree based on SNPs in the core genome of 71 
ST5-MRSA 
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SNPS: single nucleotide polymorphisms; ST5-MRSA: meticillin-Resistant Staphylococcus aureus Sequence Type 
(ST) 5; PWID: People who inject drugs. 
The tree was visualised using interactive Tree Of Life (iTOL), pairwise SNP distance matrix was calculated 
excluding Ns and gaps. 
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Maximum-likelihood phylogenetic tree based on SNPs in the core genome of 71 ST5-MRSA including: 24 
bacteraemia and 12 carriage isolates from PWID in Bristol, eight carriage (pre-admission screening) isolates 
from patients in Bristol and 27 temporally-related, geographically dispersed isolates from PHE national 
reference laboratory archives; reference genome N315 (NC002745). 
SCCmectypes are denoted on the branches. Black squares indicate PWID status and presence of genetic 
markers associated with particular resistance traits. Isolate labels are coloured according to geographic 
region. Clinical groups comprised bacteraemia infection (n = 44), non-bacteraemia infection (n = 12) and 
carriage (n = 15). A, B, C designation denotes sub-clusters within Bristol clade at 150 SNP threshold. Scale of 
branch distance represents ca 140 SNPs. 
Within the Bristol clade, three sub-clades were apparent. Sub-clade A comprised four PWID 
carriage isolates recovered in 2016. There were nine isolates in sub-clade B, recovered over a 
4-year period (2014–17), comprising four carriage and three bacteraemia isolates from PWID 
in Bristol and two bacteraemia cases with injecting status unknown: one each from London 
and the South East of England. Sub-clade C was the largest and included 33 isolates recovered 
over 6-year period (2012–17); 31 were from Bristol (25 PWID, the injecting status for the other 
six was unknown) and included 23 bacteraemia, four carriage and four non-invasive samples. 
The remaining two included one each from non-PWID in Wales and North West England. The 
remaining 23 isolates (namely, nationally representative CC5 comparator isolates including 
three from PWID in the East Midlands and three from non-PWID UHB admission screening 
samples) in the tree recovered over the same timescale (2012–17) were phylogenetically 
heterogeneous; none of the Bristol PWID isolates were represented in this group. All were 
ST5 but none encoded SCCmecIVg, although multiple other SCCmec types were apparent and, 
in contrast to the Bristol clade, few resistance traits were identified (Figure). The PWID 
carriage samples that were part of the Bristol clade. Persons with isolates from different sub-
clades varied in terms of their epidemiological metadata (Table 3). 
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TABLE 3. A description of the epidemiological metadata for PWID colonised with MRSA 
from the Bristol clade, by sub-clade, 2016 
 
Characteristic 
MRSA Bristol clade 
Sub-clade A Sub-clade B Sub-clade C Total 
Hospital contact past month 3 3 0 6 
Groin inject in the past month 2 3 3 8 
Homeless past year 3 2 3 
8 
Infection at injection site 3 1 2 6 
Previous MRSA Infection in past 3 months 1 2 0 3 
Most frequently injecting location in public places 2 1 1 4 
Frequently inject in groups of three or more 2 1 0 3 
Total 4 3 4 11 
MRSA: meticillin-resistant Staphylococcus aureus; PWID: people who inject drugs. 
In addition to SCCmecIVg, other resistance elements were also highly conserved among the 
Bristol clade isolates; specifically, Tn554 which encodes ermA and ant(9)-Ia (conferring 
resistance to erythromycin and spectinomycin respectively) and mutational resistance to 
fluoroquinolones (grlA S80F). Loss of Tn554 was apparent in seven sub-clade B isolates. 
Independent loss of this mobile element was observed in two sub-clade C isolates; a further 
two displayed mutational resistance to fusidic acid in an apparent single event (fusA V90I). 
One isolate carrying mutational resistance (ileS V588F) exhibited intermediate resistance to 
mupirocin on VITEK. 
Discussion 
We combined WGS and epidemiological data to provide novel insights into an increase in 
MRSA among PWID in Bristol. This study was instigated due to a large increase in the number 
of MRSA infections in PWID in 2014. The MRSA colonisation prevalence among PWID in Bristol 
was around six times higher than the general population (8.7% vs up to 1.5%) but is broadly 
in line with previous studies of MRSA colonisation among PWID (5.7–18.6%) [10,13,14,16]. 
This puts Bristol PWID at increased risk due to the well-defined association between 
colonisation and infection [8]. The factors associated with MRSA colonisation were PWID who 
reported injecting in public places, recent healthcare contact and injecting in groups of three 
or more and SSTI. 
The collective data indicate the establishment of a successful clade of CA-MRSA (dubbed the 
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‘Bristol clade’) associated with colonisation and infection among Bristol’s PWID population. 
The data suggest that there has been ongoing circulation and transmission within the PWID 
community over several years. More specifically, hierarchical clustering and phylogenetic 
analyses showed evidence of clonal expansion of an ST5-MRSA-IVg clade among PWID in 
Bristol between 2012 and 2017 indicating an association with this genotype and PWID risk 
group. This contrasts with the genetic heterogeneity observed among the non-PWID UHB 
admission screening samples which belonged to six different MLST-CCs. In addition, the 
Bristol clade is distinct from the dominant HA-MRSA strain circulating in the UK (CC22-
SCCmecIVh; EMRSA-15) and the epidemiological and genomic data identify it as a PVL-
negative community-associated type of MRSA [9]. Given our knowledge of MRSA 
epidemiology in hospitals in England (currently dominated by CC22-IVh and CC5-IVc), we 
regard the ST5-IVg clone identified among PWID as being a community-like MRSA because we 
have rarely noted it in hospitalised patients and the bacteraemia cases observed in PWID are 
community onset (occurring < 48h following admission to hospital). As has been noted for 
other MRSA lineages and ecological niches, we hypothesise that representatives of this clade 
have evolved and increased in fitness through adaptation to particular settings and 
populations [37]. Representatives of the Bristol clade were identified in 11 individuals where 
there was no evidence of injecting drug use (including seven pre-admission screening swabs 
from Bristol and four clinical infections occurring in geographically distinct regions in England 
and Wales). Additional information on these persons was not available, however other risk 
factors such as contact with PWID, homelessness or alcohol abuse may account for some/all 
of these cases. This is supported by evidence that networks of PWID can operate as reservoirs 
of infection with significant links to the general population [38]. This may provide evidence 
that this lineage is infiltrating wider population networks. An alternative explanation could be 
that a rare strain of MRSA from the general population has entered and spread through the 
Bristol PWID population. The study is unable to provide a definitive answer as to the source 
of this strain although we show clearly that MRSA is being spread between PWID and the 
general population. 
The data indicate an association between the presence of a specific lineage of MRSA among 
PWID and developing an invasive infection. This is supported by the smaller number or 
absence of invasive samples belonging to other lineages. This association could be 
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attributable to adaptation or tropism within this MRSA strain or the epidemiological 
characteristics of the affected groups, such as injecting practices [37]. 
A major limitation of this study is the sample size as it provided insufficient power to perform 
multivariable analysis and some of the associations could be subject to confounding. This 
issue was anticipated and the study was designed to provide a baseline from which further 
work could be conducted. Moreover, as there is no sampling frame for this population, we 
used a non-random sampling method to recruit participants. To mitigate this issue, we used 
a quota-based approach to ensure the sample was representative of the known of PWID 
population in Bristol. The age and sex distribution of our sample was similar to the PWID 
population engaged with the extensive NSP in Bristol, that involves both fixed and mobile 
programmes, as previously measured by BDP in 2015 (data not shown). The cross sectional 
design was not able to estimate incidence or rule out reverse causation between colonisation 
and risk factors. Finally, PHE reference laboratory holds data on PWID status however, this 
often poorly completed this could result in misclassification and under-estimate PWID 
exposure in all samples. 
Taken together, the high colonisation prevalence, establishment of a successful clone of CA-
MRSA within the PWID population, possible dissemination to the general population and the 
high number of invasive infections within a specific vulnerable group, we believe there is 
sufficient evidence for public health action. Currently we are not aware of any specific 
guidance in Europe or worldwide for the management of MRSA in PWID. Previous outbreaks 
have targeted enhanced wound care and basic hand hygiene interventions alongside 
improved access to healthcare; although the effectiveness of these measures remains 
untested [39]. Ideally, any intervention should be aimed towards targeting not only MRSA but 
bacterial infections in general. A more holistic approach is desirable particularly in light of 
outbreaks of invasive group A streptococci (iGAS) infections affecting PWID populations in the 
UK (2016 and 2017) and in Canada (2008). These were caused by the emergence of unusual 
strain types resulting in a substantial number of cases and could not be traced to a source 
[40-42]. A general approach is also likely to be more effective than suppression therapy on its 
own as it is widely recognised that MRSA decolonisation therapy (nasal cream and body wash) 
can be ineffective [43]. Apparent failure of eradication can be multi-factorial and, from our 
data, we do not know what treatment regimen was used and whether it was adhered to or 
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not. 
More broadly, a range of harm reduction measures have been shown to effectively reduce 
the risk of bacterial infections among PWID, such as provision of advice and education in good 
hygienic practices and basic infection prevention control [44]. Providing training in safe 
injection techniques, including cleaning of the injection site, can also lower bacterial infection 
risk [45,46]. There remains the need for upstream interventions, such as providing harm 
reduction resources, supervised injecting facilities and opioid substitution therapy, as these 
are excellent methods to reduce the overall number of infections among PWID [44,47-50]. 
The results of this study have been used to improve the post infection review process and 
develop a pilot with planned evaluation for universal supply for of Chlorhexidine wipes to 
PWID through NSP. The findings from this study provide information to help inform the 
development of targeted interventions such as community-based screening, health 
promotion messaging, wound care, skin cleaning advice and suppression therapy with 
personal and environmental decontamination (washing clothes and bedding) [39,51]. 
From a wider perspective, molecular epidemiological initiatives locally, nationally and 
internationally should be encouraged to further our understanding of clonal shifts in MRSA 
not only within at risk groups such as PWID, but across all healthcare sectors. Such studies 
should be prospective in nature and utilise a social network approach to identify high-risk 
communities and factors associated with MRSA infection. There is a need to develop and 
evaluate the feasibility of community- and hospital-based interventions to prevent MRSA in 
PWID. Current issues centre on the complexity of managing PWID as inpatients, adherence to 
treatment and re-acquisition of MRSA within the community. These groups have frequent 
hospital contact, which could negatively impact on local infection control for MRSA; 
therefore, increasing awareness of local medical staff is vital to promote screening and the 
appropriate prescribing of suppression treatment to MRSA-positive PWID as is widely 
recommended on admission to hospital. 
In conclusion, this study details the emergence of a CA-MRSA clone within Bristol’s PWID 
population that is circulating within the community and is responsible for a considerable 
number of invasive infections in PWID. Surveillance and further research are required locally, 
nationally and internationally to examine the epidemiology of this clone and identify 
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areas/people at risk. Public health action is required to mitigate this on-going risk and protect 
PWID from MRSA and other bacterial infections. 
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